Features | Partner Sites | Information | LinkXpress
Sign In
ElsMed
Schiller
Ampronix

NMR-Based Diabetes Risk Index Helps to Identify Normal-Weight Individuals at High Risk of Progressing to Type 2 Diabetes

By Medimaging International staff writers
Posted on 09 Jul 2014
A nuclear magnetic resonance (NMR)-based diabetes risk index (DRI) is being used to identify normal-weight individuals at high risk of progressing to type 2 diabetes, and may enable a more comprehensive risk assessment and intervention in at-risk patients.

LipoScience, Inc. (Raleigh NC, USA), a diagnostic company that develops personalized NMR diagnostics to further the quality of patient care in cardiovascular, metabolic, and other diseases, presented data demonstrating the utility of the company’s technology on June 14, 2014, at the 74th Scientific Sessions of the American Diabetes Association (ADA), held in San Francisco (CA, USA), and suggests that the DRI may enable more timely and focused risk assessment and intervention in at-risk individuals regardless of body weight, potentially preventing or slowing their progression to type 2 diabetes.

“Many clinicians are challenged about how to effectively manage patients with ‘intermediate’ blood glucose levels ranging from 90 to 110 mg/dL, as within this range there is often ambiguity as to whether a patient will progress to type 2 diabetes,” commented Margery Connelly, PhD, vice president, translational research of LipoScience. “The ambiguity is particularly pronounced in normal-weight individuals, who do not typically present with overtly visible risk factors. With our simple-to-use diabetes risk index, clinicians now have a tool to help them identify high-risk patients, providing guidance for implementing targeted risk-reduction strategies.”

The DRI is a clinical lab test that uses LipoScience’s proprietary NMR-derived markers of insulin resistance, inflammation, and potentially impaired B-cell function to determine a patient's risk of progressing to type 2 diabetes. DRI provides researchers and healthcare providers with the means to assess a patient’s risk of progressing to diabetes at any given level of fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), or body mass index (BMI).

The investigators used NMR data gathered at baseline from participants in the Multi-Ethnic Study of Atherosclerosis (MESA), to develop the DRI assay, and then used data from and the Insulin Resistance Atherosclerosis Study (IRAS) to verify its ability to stratify a patient’s risk of progressing to type 2 diabetes. To determine whether the DRI score was capable of identifying normal-weight individuals with a high likelihood of developing diabetes, the investigators compared the percentage of patients progressing to type 2 diabetes across quartiles of the DRI score in three BMI categories—normal weight (BMI < 25), overweight (BMI 25–30), and obese (BMI ≥ 30). Regardless of the BMI category, as the DRI score increased there was an increased likelihood of becoming diabetic, even for patients whose BMI was within the normal range. Furthermore, DRI added predictive value independently of BMI in both the MESA and IRAS populations.

"Even in the absence of being overweight, DRI can help healthcare providers make a more timely prediction of whether a patient is on the path toward developing diabetes, before blood glucose reaches so-called ‘pre-diabetes’ levels,” noted William C. Cromwell, MD, chief medical officer of LipoScience. “By providing more precise risk-assessment information, DRI can facilitate initiation of individualized patient management strategies, while motivating high-risk patients to take steps to lower their risk.”

LipoScience is focused on the new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The NMR LipoProfile test, the company’s first proprietary test, is the only US Food and Drug Administration (FDA)-cleared blood test that directly quantifies low-density lipoprotein (LDL) particles and provides physicians and their patients with actionable information to personalize management of heart disease.

The Vantera clinical analyzer is the first FDA-cleared platform that utilizes NMR technology. Its ease of use and quick turnaround time helps maximize efficiency and throughput in the clinical laboratory.

Related Links:

LipoScience



Channels

Radiography

view channel
Image: The AeroDR Premium is an extremely light cassette-type digital radiography detector with improved strength (Photo courtesy of Konica Minolta).

Cassette-Type Digital Radiography Detector Designed to Reduce Waiting Times

Key features of a new cassette-type digital radiography (DR) system includes an extremely light weight of 2.6 kg; improved load resistance and drop impact resistance; and reduced waiting time due to shortened... Read more

MRI

view channel
Image: MagLab’s 900 MHz magnet (Photo courtesy of FSU – Florida State University).

High Magnetic Field MRI Technology Provides Comprehensive Analysis of Strokes

A new, novel way to categorize the severity of a stroke, help in diagnosis, and assesse potential treatments has been demonstrated by US researchers. “Stroke affects millions of adults and children... Read more

Ultrasound

view channel
Image: Purdue University researchers are using ultrasound images like this one to study abdominal aortic aneurysms, a potentially fatal condition that is the 13th leading cause of death in the United States (Photo courtesy of Purdue University/Weldon School of Biomedical Engineering).

Ultrasound Provides Insights into Abdominal Aortic Aneurysms

Researchers are assessing the effectiveness of the use of ultrasound to study lethal abdominal aortic aneurysms (AAAs), a bulging of the aorta that is typically fatal when it ruptures, and for which there... Read more

General/Advanced Imaging

view channel
Image: A collaborative effort between EPFL, CNRS, ENS Lyon, CPE Lyon, and ETH Zürich has led to the development of a novel approach that can considerably improve the capabilities of medical imaging with safer procedures for the patient (Photo courtesy of EPFL - Ecole Polytechnique Fédérale de Lausanne).

Collaboration to Make Diagnostic Medical Imaging Less Hazardous Using Hyperpolarization Agents

A collaborative effort by scientists has led to the development of an innovative strategy that can considerably improve the capabilities of medical imaging with safer procedures for the patient.... Read more

Imaging IT

view channel
Image: The Coronis Uniti diagnostic image display supports PACS and breast imaging in color and grayscale (Photo courtesy of Barco).

Diagnostic Image Display Designed for Both PACS and Breast Imaging

The first diagnostic display designed for both picture archiving and communication systems (PACS) and breast imaging provides excellent image quality, inventive productivity features, and a focus on ergonomics.... Read more

Industry News

view channel

Global Partnership Provides Treatment Planning Support for Modulated Arc Radiotherapy

Varian Medical Systems (Palo Alto, CA, USA) Eclipse treatment planning software can now be used to plan modulated arc radiotherapy (mARC) treatments at sites using Siemens Healthcare (Erlangen, Germany) medical linear accelerators. Varian Medical Systems and Siemens Healthcare presented their range of solutions that... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.